Triple-S Management Corporation
Triple-S Management Corporation (GTS) Stock Competitors & Peer Comparison
See (GTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTS | $35.99 | +1.04% | 0 | 10.41 | $3.46 | N/A |
| UNH | $287.12 | -0.97% | 262.8B | 21.95 | $13.22 | +3.01% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $77.40 | +0.10% | 97.6B | 55.18 | $1.39 | +3.48% |
| ELV | $341.54 | -1.91% | 75.7B | 13.61 | $25.21 | +1.99% |
| CI | $281.82 | -1.43% | 74.9B | 12.64 | $22.18 | +2.16% |
| HUM | $185.31 | -2.73% | 22.8B | 17.76 | $10.69 | +1.86% |
| CNC | $43.26 | -0.96% | 21.3B | -3.15 | -$13.72 | N/A |
| MOH | $155.00 | +4.56% | 7.8B | 16.95 | $8.91 | N/A |
| ALHC | $20.35 | -2.35% | 4.1B | -187.27 | -$0.11 | N/A |
Stock Comparison
GTS vs UNH Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 262.8B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $287.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 21.95. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here
GTS vs ANTM Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here
GTS vs CVS Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 97.6B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $77.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 55.18. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.02%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here
GTS vs ELV Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 75.7B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $341.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 13.61. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here
GTS vs CI Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 74.9B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $281.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 12.64. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.15%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here
GTS vs HUM Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 22.8B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $185.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 17.76. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.07%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here
GTS vs CNC Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 21.3B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $43.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is -3.15. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of -0.28%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here
GTS vs MOH Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 7.8B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $155.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 16.95. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here
GTS vs ALHC Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 4.1B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $20.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is -187.27. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of -0.16%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here
GTS vs OSCR Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 3.4B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is -7.83. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here
GTS vs CLOV Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 1B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -18.36. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here
GTS vs BHG Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of -0.65%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here
GTS vs CABR Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CABR has a market cap of 12.1M. Regarding current trading prices, GTS is priced at $35.99, while CABR trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CABR's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to CABR's ROE of N/A. Regarding short-term risk, GTS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CABR's competition here
GTS vs BMGL Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, GTS is priced at $35.99, while BMGL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BMGL's P/E ratio is -1.21. In terms of profitability, GTS's ROE is +0.07%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, GTS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BMGL's competition here
GTS vs MRAI Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MRAI has a market cap of 7M. Regarding current trading prices, GTS is priced at $35.99, while MRAI trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MRAI's P/E ratio is -0.16. In terms of profitability, GTS's ROE is +0.07%, compared to MRAI's ROE of +0.39%. Regarding short-term risk, GTS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MRAI's competition here
GTS vs NIVF Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, NIVF has a market cap of 20.5K. Regarding current trading prices, GTS is priced at $35.99, while NIVF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas NIVF's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, GTS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check NIVF's competition here
GTS vs MGLN Comparison February 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here